AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
- Details
- Category: AstraZeneca

Under the terms of the agreement, Quell's proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock will be leveraged to develop autologous multi-modular Treg cell therapy candidates for major autoimmune disease indications.
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
- Details
- Category: Bayer

New England Journal of Medicine publishes results from Phase 3 induction and maintenance programs evaluating upadacitinib (RINVOQ®) in Crohn's disease
- Details
- Category: AbbVie

Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
- Details
- Category: Business

U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
- Details
- Category: Pfizer

Bayer launches unit to develop new precision health consumer products
- Details
- Category: Bayer

Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
- Details
- Category: Pfizer

More Pharma News ...
- Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
- FDA Advisory Committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization
- Thermo Fisher Scientific & Pfizer partner to expand localized access to next generation sequencing-based testing for cancer patients in international markets
- Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
- Bayer opens first Co.Lab Life science incubator in Cambridge
- Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
- U.S. FDA approves PREVNAR 20®, Pfizer's 20-valent pneumococcal conjugate vaccine for infants and children